Bank of America’s Japer Therapeutics Warrants JSPRW Stock Holding History

Bank of America’s Portfolio JSPRW Stock Details JSPRW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-100	Closed	-$4	–	6329
2025 Q4	$4	Sell	100 -1	-1%	–	﹤0.01%	7240
2025 Q3	$8	Buy	+101	New	+$9	﹤0.01%	8231

Other funds holding JSPRW

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

TCM

Tenor Capital Management New York $6.49B AUM 3.01% 1-Year Est. Return

Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Bank of America's JSPRW Position: Q1 2026 in Review

Bank of America sold out of Japer Therapeutics Warrants (JSPRW) in Q1 2026, closing a stake of 100 shares — an estimated $4 sold.

Bank of America first reported a position in JSPRW in Q3 2025 and held it in 2 quarters. The position peaked at $8 in Q3 2025. 7 funds tracked by Wall St. Rank hold JSPRW as of Q1 2026.

Bank of America reported no remaining Japer Therapeutics Warrants position as of Q1 2026 after selling out during the quarter.
Bank of America sold 100 Japer Therapeutics Warrants shares in Q1 2026, an estimated $4.
Bank of America first reported a position in Japer Therapeutics Warrants in Q3 2025 and held it in 2 quarters.
Bank of America's Japer Therapeutics Warrants position peaked at $8 in Q3 2025.
7 funds tracked by Wall St. Rank held Japer Therapeutics Warrants as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.